Abstract No. 9534 Phase 1b/2, Open Label, Multicenter, Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced Melanoma Who Are Naïve to Anti-PD-1/L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870).

by Michael Persons | Jun 1, 2019 | Immunomodulation, Publications and Presentations